Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
Study Details
Study Description
Brief Summary
This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program.
This study has two objectives:
-
Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients.
-
Understanding characteristics of patients within each nintedanib adherence trajectory among IPF patients.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Idiopathic Pulmonary Fibrosis Patients Medicare beneficiaries with IPF who newly initiated treatment with nintedanib |
Drug: Nintedanib
Nintedanib
|
Outcome Measures
Primary Outcome Measures
- Adherence trajectories based on monthly proportion of days covered (PDC) [up to 12 months]
Eligibility Criteria
Criteria
Inclusion criteria:
-
Newly initiated nintedanib during 10/01/2014 to 12/31/2018
-
Were at least 66 years old as of the date of their first nintedanib prescription claim (index date)
-
Qualified for Medicare based on age
-
Had at least 12 months (365 days) of continuous enrollment in Medicare Parts A, B and D before (baseline period) and 12 months (360 days) after the index date (follow-up period)
-
Had at least one inpatient or two outpatient claims (>14 days apart) with a diagnosis code for Idiopathic Pulmonary Fibrosis (IPF) during the baseline period
Exclusion criteria:
-
Had any history of pirfenidone or nintedanib use during the baseline period
-
Had any history of lung transplant during the baseline, index date or follow-up periods
-
Had any claims for skilled nursing facility, long-term care facility or hospice during the baseline, index date or follow-up period
-
Had evidence during the baseline period of any of the following conditions: lung cancer, autoimmune, or connective tissue diseases (i.e. rheumatoid arthritis (RA), sarcoidosis, systemic lupus erythematosus (SLE), dermatopolymyositis, systemic sclerosis, Sjogren's, and mixed connective tissue disease (CTD)) during the baseline period
-
Had dual eligibility of Medicare and Medicaid
-
Had history of using pirfenidone at the same time with nintedanib during follow-up
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Medicus Economics, LCC | Milton | Massachusetts | United States | 02186 |
Sponsors and Collaborators
- Boehringer Ingelheim
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 1199-0471